|
|
 |
|
Viewing report
|
|
|
|
Healthcare Reform in China
Business Insights, Oct 2011, Pages: 112
This report gives an overview of China’s demographics, overall healthcare infrastructure, and the need for healthcare reforms. It provides detailed coverage of China’s healthcare reform plans from the viewpoint of pharmaceutical companies, payers, and healthcare providers. Reforms and implications for various stakeholders are assessed and comments from 23 managers at Chinese hospitals included.
Features and benefits:
- Learn how healthcare is being reformed in China and the effects on various industry stakeholders.
- Develop strategies for successful market penetration in China.
- Understand the regulatory structures which affect how drugs are approved and reimbursed in China.
- Gain insights about the effects of reform from a Scrip Business Insights survey of 23 managers at Chinese hospitals.
- Evaluate the importance of tier 2 and 3 cities in China's pharmaceutical market.
Highlights:
- Historically, China had a very high out-of-pocket expenditure on healthcare. However, the proportion of out-of-pocket expenditure on healthcare dropped from 60% in 2001 to 40% in 2008 due to the increasing coverage of social health insurance schemes.
- China’s population will increase by 85m people between 2010 and 2020. 85% of this will be accounted for by an increase in the population of over 60s, which will prompt growth in markets for cardiovascular diseases, dementia, and other age-linked conditions. A sharp rise in lifestyle diseases such as diabetes and obesity is also underway.
- Reforms are set to present opportunities for pharma companies, CROs, medical device manufacturers, and private health insurance providers. Healthcare IT is also set for a boost, as the government begins to invest in electronic health records.
Your key questions answered:
- How is healthcare provision in China changing, and how can pharma companies capitalize on this?
- How will healthcare reform in China affect CROs and clinical research?
- What are the opinions of Chinese hospital managers on the effects of reform?
- What are the advantages and disadvantages for a company to have a product listed on the national drug reimbursement lists?
- How will medical device manufacturers and private health insurance providers be affected by healthcare reforms?
|
|
|
|
